RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post-market Surveillance), End User (Pharma, Payer) - Global Forecast to 2029

RWE Oncology Solutions Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post-market Surveillance), End User (Pharma, Payer) - Global Forecast to 2029

The RWE oncology solutions market is expected to grow at a CAGR of 14.2% from 2022–2029 to reach $1.65 billion by 2029.

After a comprehensive primary and secondary research and an in-depth analysis of the market scenario, this report provides insights into key industry drivers, restraints, challenges, and opportunities of the RWE oncology solutions market.

The growth of this market is driven by factors such as the rising prevalence of cancer, rapidly growing big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare. Furthermore, emerging markets, rising focus on end-to-end RWE services, and rising adoption of mobile applications and wearable devices and AI in RWE are expected to provide significant growth opportunities for market players and new entrants in this market.

Based on component, in 2022, the real-world datasets segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the growing amount of medical data generated in hospitals, increasing dependence on outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.

Based on application, in 2022, the drug development & approvals segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the rising number of cancer cases, compelling pharmaceutical and biopharmaceutical companies to focus on drug development for cancer treatment. The effective deployment of RWE can significantly accelerate the pace of discovery, enable drug approvals, and help understand the impact of new oncology therapies, boosting the growth of this segment.

Based on end user, in 2022, the pharmaceutical & medical device companies segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the importance of RWE studies in cancer drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

An in-depth analysis of the geographical scenario of the RWE oncology solutions market provides detailed qualitative and quantitative insights into the five major geographies (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2022, North America is expected to command the largest share of the global RWE oncology solutions market, followed by Europe and Asia-Pacific.

Some of the key companies operating in the RWE oncology solutions market include IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

Scope of the Report:

RWE Oncology Solutions Market, by Component

Real-world Datasets
Disparate Datasets
EMR/EHR/Clinical Data
Claims & Billing Data
Pharmacy Data
Cancer Registries
Other Disparate Datasets
Integrated Datasets
Real-world Consulting & Analytics Services

(Note: Other Disparate Datasets include data generated from mobile applications, wearable devices, and social media).

RWE Oncology Solutions Market, by Application

Drug Development & Approvals
Market Access & Reimbursement/Coverage Decisions
Post-market Surveillance
Medical Device Development & Approvals
Other Applications

(Note: Other Applications include regulatory and clinical decision-making).

RWE Oncology Solutions Market, by End User

Pharmaceutical, Biotechnology, and Medical Device Companies
Healthcare Payers
Healthcare Providers
Other End Users

(Note: Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies).

RWE Oncology Solutions Market, by Geography

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe (RoE)
Asia-Pacific (APAC)
Japan
China
India
South Korea
Taiwan
Singapore
Rest of APAC (RoAPAC)
Latin America
Middle East & Africa

Real World Evidence Solutions Market - Report Summary

Report Metrics	Details
Years Considered	2020 - 2029
Base Year	2021
Forecast Period	2022-2029
Page Count	201
Units Referenced	Value (USD Million/Billion)
Segments/Key Topics	Market by Component, Market by Application, Market by End User, Market by Geography Geography
Regions Covered	North America, Europe, Asia-Pacific, Latin America , and Middle East & Africa
Key Companies Mentioned	Anthem, Inc. (U.S.), IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), Parexel International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.)

FAQs About the Report

What is the current value of revenue generated by the RWE oncology solutions market? At what rate is the global demand for RWE oncology solutions projected to grow in the next 5–7 years?

The RWE oncology solutions market is expected to reach a value of $1.45 billion by 2029, with a CAGR of 13.8% from 2022–2029.

Which component segment showcases high-growth opportunities for the players operating in the RWE oncology solutions market?

Based on component, the consulting services segment is slated to register the highest growth rate during the forecast period and provide significant opportunities for players operating in this market.

Which application segment showcases high growth opportunities for the players operating in the RWE oncology solutions market?

Based on application, the drug development & approvals segment is slated to register the highest growth rate during the forecast period and provide significant opportunities for players operating in this market.

What are the Major Drivers for this Market?

Major drivers of the market include:

Shift to Value-based Care
Rising Focus on Personalized Healthcare
Growing Burden of Cancer
Rapidly Growing Big Data in the Healthcare Sector
Delays in Drug Development & the Consequent Increase in Development Costs

What are the major restraints for the global RWE oncology solutions market?

Major restraints of the market include:

Reluctance to Rely on Real-world Studies

Who are the major players operating in the RWE oncology solutions?

The major key players operating in the RWE oncology solutions market are Anthem, Inc. (U.S.), IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), Parexel International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).

Which are the high-growth countries/regions in the market?

Asia-Pacific is slated to register significant market growth during the forecast period of 2022–2029. The high market growth in Asia-Pacific is driven by growing demand for data defining the value and effectiveness of medicines by payers, growing demand for real-world studies in drug R&D, and increasing government interest in using real-world studies for regulatory decision-making.